Publications Repository

Publications Repository

Search 
  •   Home
  • ICR Divisions
  • Cancer Biology
  • Search
  • Home
  • ICR Divisions
  • Cancer Biology
  • Search
JavaScript is disabled for your browser. Some features of this site may not work without it.

Search

Show advanced filtersHide advanced filters

Filters

Use filters to refine the search results.

Now showing items 71-77 of 77

  • Sort Options:
  • Relevance
  • Issue date (newest)
  • Issue date (oldest)
  • Results Per Page:
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
Thumbnail

Synergistic antitumour effects of rapamycin and oncolytic reovirus. 

Comins, C; Simpson, GR; Rogers, W; Relph, K; Harrington, K; et al. (2018-06)
There are currently numerous oncolytic viruses undergoing clinical trial evaluation in cancer patients and one agent, Talimogene laherparepvec, has been approved for the treatment of malignant melanoma. This progress ...
Thumbnail

Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma. 

Wilkinson, MJ; Smith, HG; Pencavel, TD; Mansfield, DC; Kyula-Currie, J; et al. (2016-09)
The management of locally advanced or recurrent extremity sarcoma often necessitates multimodal therapy to preserve a limb, of which isolated limb perfusion (ILP) is a key component. However, with standard chemotherapeutic ...
Thumbnail

Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. 

Burley, TA; Mączyńska, J; Shah, A; Szopa, W; Harrington, KJ; et al. (2018-06)
Glioblastomas (GBMs) are high-grade brain tumors, differentially driven by alterations (amplification, deletion or missense mutations) in the epidermal growth factor receptor (EGFR), that carry a poor prognosis of just ...
Thumbnail

Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment. 

Ip, LRH; Poulogiannis, G; Viciano, FC; Sasaki, J; Kofuji, S; et al. (2015-04)
Treatment options for ovarian cancer patients remain limited and overall survival is less than 50% despite recent clinical advances. The lipid phosphatase inositol polyphosphate 4-phosphatase type II (INPP4B) has been ...
Thumbnail

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. 

Samson, A; Scott, KJ; Taggart, D; West, EJ; Wilson, E; et al. (2018-01)
Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined ...
Thumbnail

Sex specific retinoic acid signaling is required for the initiation of urogenital sinus bud development. 

Bryant, SL; Francis, JC; Lokody, IB; Wang, H; Risbridger, GP; et al. (2014-11)
The mammalian urogenital sinus (UGS) develops in a sex specific manner, giving rise to the prostate in the male and the sinus vagina in the embryonic female. Androgens, produced by the embryonic testis, have been shown to ...
Thumbnail

CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy. 

Barker, HE; Patel, R; McLaughlin, M; Schick, U; Zaidi, S; et al. (2016-09)
Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer-related deaths, with increasingly more cases arising due to high-risk human papillomavirus (HPV) infection. Cisplatin-based chemoradiotherapy is a ...
  • «
  • 1
  • . . .
  • 5
  • 6
  • 7
  • 8

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types

Discover

AuthorHarrington, Kevin (29)Choudhary, Jyoti (14)Melcher, Alan (13)Mansfield, David (10)Pardo Calvo, Maria Mercedes (10)... View MoreSubject
Animals (77)
Humans (55)Mice (50)Cell Line, Tumor (33)Female (26)... View MoreDate Issued2019 (21)2018 (13)2017 (22)2016 (13)2015 (3)2014 (3)2013 (1)2012 (1)Publication TypeJournal Article (77)
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.